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Abstract—The National Institutes of Health (NIH)
launched the Rapid Acceleration of Diagnostics
(RADxSM) Tech initiative to support the development
and commercialization of novel severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) point-of-care test
devices. The primary objective of the Clinical Studies Core
(CSC) was to perform SARS-CoV-2 device studies involving
diverse populations and settings. Within a few months, the
infrastructure for clinical studies was developed, including
a master protocol, digital study platform, data management
system, single IRB, and multi-site partnerships. Data from
some studies are being used to support Emergency Use
Authorization of novel SARS-CoV-2 test devices. The CSC
reduced the typical time and cost of developing medical
devices and highlighted the impactful role of academic
and NIH partnership in addressing public health needs
at a rapid pace during a global pandemic. The structure,
deployment, and lessons learned from this experience
are widely applicable to future in vitro diagnostic device
clinical studies.
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I. INTRODUCTION
T he World experienced the emergence of a novel coron-avirus in December 2019 in central China, which was
declared a global pandemic by the World Health Organization
in March 2020. The International Committee on Taxonomy of
Viruses named this virus severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), and the World Health Organi-
zation assigned the term coronavirus disease 2019 (COVID-19)
to the lower respiratory tract disease caused by SARS-CoV-2.
The first case of COVID-19 in the United States was diagnosed
in January 2020, shortly after which the U.S. Department of
Health and Human Services declared a public health emer-
gency. SARS-CoV-2 spread rapidly throughout the U.S., soon
exceeding public health laboratory capacity to keep pace with
the demand for diagnostic testing. The Food and Drug Ad-
ministration (FDA) authorized a test developed by the Centers
for Disease Control and Prevention (CDC) via an Emergency
Use Authorization (EUA) on February 4, 2020, which permit-
ted use of a non–FDA-approved test device to respond to an
emergency.
Mitigating strategies to reduce propagation of the pandemic
centered on wearing masks, social distancing, and timely testing
[1], [2]. However, the United States had insufficient capacity for
rapid SARS-CoV-2 testing that would reduce public health risk
and elucidate the true burden of infection [3]–[5]. Consequently,
the National Institutes of Health (NIH) received an appropriation
from Congress in April 2020 to increase the United States
capacity to conduct SARS-CoV-2 viral antigen and nucleic acid
testing [6]. In an effort to support the development, validation,
and commercialization of these tests, the NIH launched the
Rapid Acceleration of Diagnostics (RADxSM) Tech initiative
and challenged scientists to develop rapid SARS-CoV-2 diag-
nostic testing and screening technologies that could be deployed
across the country in diverse populations and settings [7].
Here we describe creation of the RADx Tech Clinical
Studies Core (CSC) by leveraging existing infrastructure and
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multidisciplinary expertise from leading academic healthcare
centers across the United States. We also illustrate the principles
of team science and coordination that grounded our approach.
II. OBJECTIVES
The primary objective of the CSC was to design and imple-
ment SARS-CoV-2 diagnostic device clinical studies involving
diverse use-case populations and settings.
COVID-19 has affected segments of the U.S. population
that have traditionally experienced disparities across a myriad
of health conditions [8]–[10]. Priority populations for clinical
studies were thus communities that have and will likely continue
to experience a high burden of COVID-19, such as Native Amer-
ican/American Indian populations, African Americans, Latinx
communities, certain Asian groups, and others who have borne a
disproportionate share of the morbidity and mortality attributed
to COVID-19 [10]–[16]. In addition, urban areas of the U.S.
were hit hardest early in the pandemic, while more recently,
rates of COVID-19 are increasing in many rural areas across the
country [17], [18]. Regardless of geography or socio-economic
status, those in congregate facilities such as nursing homes or
prisons have experienced particularly high rates of COVID-19
mortality [16], [19], [20]. Inclusion of multiple research sites
across the U.S. allowed the CSC to draw on the relationships
between each institution and its local communities to maximize
opportunities for study enrollment.
In addition, SARS-CoV-2 diagnostic technologies need to
be rigorously evaluated not only for technical performance
characteristics, but also in the context of “real-world” use. The
entire testing workflow must be evaluated for its usability in the
populations and settings for which it is intended. Moreover, a
mechanism for reporting and disseminating test results need to
be established for both individual and public health purposes.
Providing these resources, the RADx Tech CSC highlights the
impactful role of academic and NIH partnership in addressing
public health needs at a rapid pace during a global pandemic. The
structure, deployment, and lessons learned from this experience




First established in 2009 by NIH National Institute of Biomed-
ical Imaging and Bioengineering (NIBIB) and now supported
by multiple NIH Institutes and Offices lead by NIBIB, the
Point-of-Care Technologies Research Network (POCTRN) was
well-positioned to apply its mission to drive the development
of point-of-care diagnostics in the context of the SARS-CoV-2
pandemic [21]. The RADx Tech CSC was developed by the
Center for Advancing Point of Care Technologies (CAPCaT) in
Heart, Lung, Blood, and Sleep Diseases, a POCTRN technology
hub and an offshoot of a highly successful medical product incu-
bator, the Massachusetts Medical Device Development Center
(M2D2) at the University of Massachusetts Lowell (UML) and
Medical School (UMMS) campuses [22]. Similarly pivoting
from their respective areas of focus, other POCTRN centers at
Northwestern (NU), Emory (EU), and Johns Hopkins (JHU)
Universities were integral to CSC development and clinical
study implementation. The Center for Innovation in Point-of-
Care Technologies for HIV/AIDS at Northwestern University
(C-THAN) provides expertise and support for development of
diagnostic devices and assays used to screen, diagnose, and mon-
itor HIV and its associated co-morbidities including viral hepati-
tis, tuberculosis, and cancers. While its network includes seven
African academic partners, C-THAN has pivoted for RADx Tech
to focus on Chicago with domestic partners Howard Brown
Health Center and ACCESS Community Network. The Johns
Hopkins Center for POC Technologies Research for Sexually
Transmitted Diseases provided expertise developing sexually
transmitted infections in vitro diagnostic devices from proof-of-
concept to clinical performance evaluation (see Robinson et al,
Clinical Review Committee in this issue). The Atlanta Center for
Microsystems Engineered Point-of-Care Technologies (ACME
POCT) is a disease-agnostic inter-institutional entity spanning
Emory University, Georgia Institute of Technology, and Chil-
dren’s Healthcare of Atlanta that focuses on the development
and translation of microsystems-engineered technologies, and
brought its unique combination of clinical and technical exper-
tise to SARS-CoV-2 diagnostics. The NIH National Heart, Lung,
and Blood Institute (NHLBI) provided oversight and funding
for infrastructure, operations, and partnerships needed by the
CSC to perform all clinical studies (U54HL143541-02S1 and
U54HL143541-02S2).
B. New Design
Applications for individual novel devices for SARS-CoV-2
detection progressed through the RADx Tech pipeline as de-
scribed in other articles in this special issue, which included
resources through the CSC to evaluate device performance and
usability in prospective human studies. The CSC organizational
framework consisted of two co-principal-investigators, an ad-
ministrative team, and four other teams based on their roles
in implementing clinical studies (Fig. 1). These teams were
led by co-investigators with critical expertise in clinical study
design, biostatistics, human subjects research, study logistics,
and community engagement. Branding with the COVID-19 Test
Us, COVID-19 Test Us Kids, and COVID-19 Test Us Bank
names and logos provided consistent and recognizable signs of
RADx Tech clinical studies.
The CSC Study Design and Analysis (SDA) Team devel-
oped the platform trial design in which multiple devices were
studied in the context of a single disease in a perpetual manner.
Because devices were ready for prospective clinical studies
at different times and the duration of their studies may vary,
this study design allowed devices to enter the platform at any
time, and similarly to leave at any time upon successful com-
pletion of enrollment or for unsuccessful results identified on
interim analysis. Use of a master protocol and consent, standard
templates, and device and site-specific modular amendments
provided flexibility to test a variety of technologies designed
for multiple environments (e.g., self-administered test at home
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Fig. 1. Clinical studies core organizational structure.
or clinician-administered point-of-care test in a medical office
or skilled nursing facility), and allowed rapid Institutional Re-
view Board (IRB) review and standardization across studies
[23]. Throughout and at the end of device studies, the SDA
Team monitored enrollment goals, data integrity, and device
performance in real time. In addition, an independent Data and
Safety Monitoring Board (DSMB) established by NHLBI had
oversight of the device studies seeking EUA from the FDA,
and met at least monthly to examine participant enrollment and
safety, device performance, and provide recommendations to
the NHLBI. The SDA Team generated detailed study reports
for review by CSC leadership, the NIH, and DSMB based
on datasets within the digital platform. They also harmonized
these datasets for submission to the NIH COVID-19 RADx
Data Hub, a centralized repository and analytical toolkit for
de-identified SARS-CoV-2 testing data available to researchers
(https://test.radx-hub.nih.gov/home).
All RADx Tech COVID-19 Test Us, Test Us Kids, and Test Us
Bank studies were executed entirely through the NIH-supported
Eureka digital study platform developed at the University of
California San Francisco (UCSF) as a resource for mobile health
research. The Eureka platform was selected based on its track
record of conducting a variety of digital studies (currently 40
studies engaging over 400000 participants) and rapidly deploy-
ing a fully digital study within weeks. Rather than build a new
mobile app for each study, participant-tested workflows are used
to customize study activities that can be dynamically updated to
the Eureka mobile app. Moreover, the Eureka team that runs the
platform has expertise in the design and implementation of dig-
ital studies, which was leveraged for the rapid cycle deployment
required for CSC device studies. The platform is available as
a web-based interface and a mobile app (iOS and Android), is
HIPAA compliant, runs on Amazon Web Services (AWS), and
provides for scalability, redundancy, security, and data integrity.
For CSC projects, participants engaged with Eureka to assess
eligibility for a device study, provide consent, and complete
digital surveys. An initial survey contained questions about de-
mographics, substance use, medical conditions, and COVID-19
experience including infection history, symptoms, treatment,
and vaccination status. After samples were collected, a second
survey asked about result interpretation and device usability.
All study steps within Eureka were supported by a messaging
system utilizing email, SMS, and/or push notification. Research
staff managed their site participants through a secure study
management portal, including a collection of triggerable digital
case report forms that open and close with time windows used
to enter device test results and other participant-specific data.
The CSC workflow (Fig. 2) began with a 2-step intake process
focused on understanding the regulatory goals and timeline
of the company and the intended use and technical aspects
of the device. Multi-party contracting proceeded in parallel.
Based on this assessment, the writing team met daily to create
device-specific protocols with the overall objective to test the
performance (as positive percent agreement and negative percent
agreement), usability, feasibility, and safety of the device. Every
protocol included a comparator SARS-CoV-2 assay (performed
via partnership with Quest Diagnostics in Marlborough, MA or
a local site CLIA certified reference laboratory) and fulfilled
other requirements for FDA EUA. Protocol development was
a collaborative process with engagement from sponsors, the
Eureka build team that customized workflows for each device
study, regulatory consultants, NHLBI Program Officers, the
DSMB, and study sites. Linked but discrete device and site
protocol modules separated consistent from variable content
thus streamlining review and modification, and allowed flexible
site recruitment strategies appropriate for local testing demand
and practices. Embedded in this process, the CSC Ethics and
Human Subjects Oversight (EHSO) Team ensured that all
study documents were written according to regulations for the
conduct of human subjects research, advised on best practices,
addressed any ethical challenges, and performed pre-review
before submission to the IRB. The CSC single IRB was based at
UMMS with reliance agreements with affiliate research center
IRBs managed by the EHSO Team.
Study protocols, materials, and Eureka content were also
developed with leadership and guidance from the Community
Health Equity and Engagement (CHEE) Team, which was
created so that novel SARS-CoV-2 tests would have a strong
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Fig. 2. Clinical studies core project workflow.
likelihood of usability and acceptability across diverse popula-
tions and settings throughout the United States. The CHEE Team
ensured CSC commitment to diversity, inclusivity, and patient-
centered research. Given its broad charge, the CHEE Team as-
sembled a two-fold approach that included six faculty members
from the University of Massachusetts Schools of Medicine and
Nursing who have scientific and/or clinical expertise working
with CSC priority populations and settings as well as health
equity and community engagement more generally. Activities
lead by the CHEE Team included reviewing all CSC study doc-
uments for appropriate literacy levels, measures, and materials,
developing a culturally representative website, outreach, and
recruitment tools, making all participant interfaces available in
both English and Spanish, and creating dissemination resources
for CSC study participants.
In parallel with development of study protocols, the Study Lo-
gistics Team managed all aspects of study preparation and im-
plementation. CSC device studies were conducted in partnership
with a robust network of research sites, thus ensuring ethnically,
geographically, and economically diverse study cohorts. The
academic centers of POCTRN – UMMS, Northwestern, Johns
Hopkins, and Emory Universities – each conduct research at a
variety of sub-sites. In addition, the Agency for Healthcare Re-
search and Quality-affiliated Practice-Based Research Network
(PBRN) includes groups of primary care practices and clinicians
who collaborate to conduct applied research projects and quality
improvement initiatives, and to translate evidence into practice
in order to address local urban and rural community health chal-
lenges. PBRNs span the country and largely serve populations
that experience health disparities, including racial and ethnic mi-
nority populations. In particular, Oregon Rural Practice-Based
Research Network, Kansas Patients and Providers Engaged in
Prevention Research, Iowa Research Network, and the Southeast
Regional Clinicians’ Network / Morehouse School of Medicine
collaborated with the CSC as study sites. The Logistics Team
established necessary legal agreements between UMMS and
research centers, followed by extensive site onboarding that
included review of standard operating procedures and training on
the Eureka platform. They tracked and ensured timely shipping
and receiving of devices, created research staff workflows for
participant enrollment and sample collection, interfaced with
sites on study implementation, and supported many other activ-
ities critical to the successful completion of device studies.
C. Clinical Studies
While most clinical studies were designed to support EUA for
novel SARS-CoV-2 diagnostic devices based on FDA require-
ments, the CSC is also pursuing other types of studies.
To support future research, a curated biorepository called
COVID-19 Test Us Bank is being launched at JHU and UMMS
to store and catalogue clinical samples obtained from par-
ticipants who also complete the digital survey. For example,
details about vaccination status, COVID-19 treatment, and
SARS-CoV-2 infection history of Test Us Bank sample donors
would be valuable for understanding infectivity or transmis-
sion of viral variants in these populations. This bioreposi-
tory will offer value to SARS-CoV-2 investigators and RADx
Tech-supported companies looking to use banked specimens
for EUA.
The CSC also launched a study to support development of a
novel approach to SARS-CoV-2 home testing called COVID-19
Test at Home. The study evaluated the feasibility of home
testing by pairing an application created by the software de-
veloper CareEvolution and the QuickVue SARS Antigen Test
developed by the diagnostics manufacturer Quidel. The app
is intended to instruct participants on appropriate use of the
test and facilitate correct interpretation of results by allowing
participants to upload smartphone images of the test strips to
the CSC database, thereby simulating an approach that might
be used by a healthcare system or public health office to track
results. The findings of this study may inform development of
digital platforms to support clinical and research programs for
SARS-CoV-2 population-based home testing.
IV. LESSONS LEARNED
The CSC encountered many challenges and opportunities
for innovation. The salient lessons learned are summarized in
Table I. Given the rapid timeline, the infrastructure and oper-
ations framework for the CSC itself were developed simulta-
neously with clinical study protocols and collaborations with
study sites. Moreover, critical elements common to all functional
areas included communication and coordination across CSC and
external teams. Regular and often concurrent multidisciplinary
meetings spanning 7 days a week were required of the CSC
teams and staff, the Eureka team, NHLBI Program Officers,
and device companies. A central accessible document repository
allowed secure sharing according to roles and needs. Balancing
comprehensiveness with speed was a daily endeavor and guided
all decisions as advancement and redirection occurred in paral-
lel, and progress was made iteratively based on accumulating
knowledge and experience. At the same time, SARS-CoV-2
national priorities, governmental agency guidelines on sampling
and testing strategies, COVID-19 clinical management, and un-
derstanding of SARS-CoV-2 pathogenesis (e.g., viral dynamics
or emergence of viral variants) were co-evolving with RADx
Tech and the CSC, which added multi-faceted complexity. While
keeping their focus on ending the SARS-CoV-2 pandemic, CSC
members together developed a culture of mutual respect, pa-
tience, support, and professionalism that has persisted over the
course of RADx Tech clinical studies.
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TABLE I
CLINICAL STUDIES CORE LESSONS LEARNED
Our teams learned to expect change, at times by the hour,
and this unpredictability drove new approaches and higher
levels of efficiency. Leveraging existing resources and part-
nering with ongoing initiatives were often the most effective.
For example, the Commonwealth of Massachusetts created the
“Stop the Spread” (STS) program to provide low barrier, free
of cost, and easy to access SARS-CoV-2 testing to all state
residents (https://www.mass.gov/info-details/stop-the-spread).
As the largest healthcare provider in central MA, the UMass
Memorial Healthcare (UMMHC) system joined STS to host
and staff community testing events in neighborhoods throughout
Worcester, MA. Based at UMMS on the medical center campus,
the CSC partnered with UMMHC to stage clinical study re-
cruitment stations at community events. Attendees could receive
their SARS-CoV-2 test as part of the event or by enrolling in a
device study. Similar recruitment strategies were undertaken at
the clinical research center, ambulatory clinics, and inpatient
units at the medical center. Tasked with accommodating a va-
riety of novel devices, anticipating technical needs (including
sufficient power sources at a myriad of outdoor community
event settings), and ensuring appropriate sample transport, the
Logistics Team and research coordinators were vital contributors
to study operations.
While existing resources were particularly useful, the relent-
less pandemic and the increasing demand for testing and other
SARS-CoV-2 research required anticipating needs and creating
new assets. For example, the standardized digital survey ques-
tions in Eureka for study participants required not only updating
but also alignment with the NIH COVID-19 RADx Data Hub.
Questions about vaccination and treatments were recently added
to the survey to reflect trends in COVID-19 prevention and
clinical management.
V. CONCLUSION
The RADx Tech Clinical Studies Core was charged with
testing SARS-CoV-2 diagnostic technologies in the diverse pop-
ulations and settings in which they would be used. Within only a
few months, the infrastructure for these studies was developed,
including a platform study design with single IRB and stan-
dard documents, a digital study platform and data management
system, mechanisms for community engagement, and multi-site
collaboration. As part of the NIH RADx Tech initiative, the Clin-
ical Studies Core reduced the typical time and cost of developing
medical devices, and highlighted the impactful role of academic
and NIH partnership in addressing public health needs at a rapid
pace during a global pandemic [24]. The structure, deployment,
and lessons learned from this experience are widely applicable
to future in vitro diagnostic device clinical studies.
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